Two series of antigenic variants of influenza virus type A, PR8 strain, have been characterized serologically (1, 2). In the original series, seven variants derived in succession in mice immunized with the homologous virus showed a progressive deviation from the parent PR8-S virus when tested with PR8-S antiserum. However, all variants continued to produce some antibody reacting with PRS-S virus. The fifth and sixth variants produced antibody with significantly less cross-reaction to PR8-S virus, but antiserum of the seventh variant showed somewhat higher levels of PR8-S antibody resembling in this respect the antisera of the first four variants. By cross-absorption tests, it was shown that the variants contained new antigenic components which were shared in different amounts.
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(Received for publication, February 6, 1958) Two series of antigenic variants of influenza virus type A, PR8 strain, have been characterized serologically (1, 2). In the original series, seven variants derived in succession in mice immunized with the homologous virus showed a progressive deviation from the parent PR8-S virus when tested with PR8-S antiserum. However, all variants continued to produce some antibody reacting with PRS-S virus. The fifth and sixth variants produced antibody with significantly less cross-reaction to PR8-S virus, but antiserum of the seventh variant showed somewhat higher levels of PR8-S antibody resembling in this respect the antisera of the first four variants. By cross-absorption tests, it was shown that the variants contained new antigenic components which were shared in different amounts.
The second series of four variants were derived from the third variant of the original series by passage in mice immunized with PRS-S virus. Subsequent variants were developed in mice given polyvalent vaccine composed of PR8-S virus and the preceding variant. In this series the first variant was not serologically different from its parent.
However, the three subsequent variants showed marked serological deviation from the variants of the original line. They reacted only slightly with PRSantiserum and provoked only small amounts of antibody which reacted with the PRS-S virus. The results of cross-protection tests in mice also reflect the marked antigenic differences noted in the H.I. and neutralization tests. These along with the results of experiments to show virulence, antigenicity and immunogenicity of some of the variants of both series compared to the original PRS-S virus will be given in this report.
Materials and Methods
The methods employed in the production of the two sedes of variants of PR8-S virus and the serological procedures used to characterize them serologically have been described in previous reports (1, 2). The details of the tests for demonstrating comparative virulence antigenicity, immunogenicity, and cross-protection will be given in the appropriate sections under Results.
RESULTS

Pathogenicity (Virulence) of the Variant Viruses for Mice and Chick
Embryos.--It was anticipated that the method employed in the production of the variants would not favor the selection of non-virulent strains. However, while there was no obvious evidence that the PR8-S variants differed in their ability to infect and kill mice and eggs, tests were carried out to determine their comparable pathogenicity.
Individual mouse lung virus suspensions with PR8-S or its variant were prepared. Groups of five normal mice each weighing 19 to 22 gin. were inoculated intranasally under light ether anesthesia with 0.05 ml. of a 10 4 dilution of each lung-virus suspension. At 48 hours after inoculation the mice of each group were killed, their lungs pooled, and ground in sterile sand. Ten per cent suspensions of stock viruses were prepared. Each lot of sterile virus was then divided into small aliquots, quickly frozen, and stored at --50°C. EID60 and LDs0 titers were then determined on each lung virus suspension. Five 10 day fertile eggs and five mice were inoculated respectively with 0.2 nil. intraaUantoieally and 0.05 ml. intranasally with each tenfold dilution of a given virus suspension.
The results are shown in Table I . As can be seen the EID~o and LD60 titers of the original PR8-S virus and the variant viruses of both series were essentially the same. This is also seen on inspection of ratios of the EIDs0 and LD60 titers. Furthermore, examination of the time of death of mice inoculated intranasally with tenfold dilutions of PR8-S or variant viruses failed to show any significant difference.
Antigenic Potency of PRS-S and Variant
Viruses.--During the development of the two series of PR8-S variants it was noted that while all variants appeared to retain the same degree of virulence or pathogenicity for mice and chick embryos there was a progressive loss in the ability of each successive variant to produce homologous antibody. In order to evaluate on a comparative basis the ability of the different variants to produce antibody the following experiments were carried out.
Monovalent formalin-inactivated allantoic fluid vaccines, one with 128 HA units and the other with 8 HA units of virus, were prepared with the PR8-S virus and each variant. A group of five mice each weighing 19 to 22 gin. was given intraperitoneally 0.5 ml. each of the high titer vaccine and another group of mice the same amount of the low titer vaccine.
Fourteen days after inoculation the five mice from each group were bled from the axillary vein. The blood was pooled and serum H.I. and in ovo neutralizing antibody titers for homologous antibody were determined. Also to demonstrate the loss of antigenic potency of the variant viruses, sera from mice surviving the virulence tests and showing pulmonary lesions were tested for homologous antibody. The results are shown in Table II .
It can be seen that the PR8-S virus produced the greatest antibody response following both vaccination and infection. Among the variant viruses the antibody response progressively decreased to the point where no antibody could be detected in the sera of mice vaccinated with 8 shown in Table II , also showed a similar decrease with each succeeding variant.
Immunogenidty of Low and High Potency Antigens.--To demonstrate the
effect of different antigenic responses upon resistance to homologous challenge with equally pathogenic viruses, Fd/s variant, a poor antigen, was compared with PR8-S, a good antigen.
A first egg passage aUantoic fluid harvest vaccine was prepared with each strain and inactivated with formalin. From each vaccine three lots each respectively containing 640, 80, and 10 HA units were prepared. Groups of 25 mice were then inoculated with a given lot, each mouse receiving 0.5 ml. intraperitoneally. Fourteen days after vaccination each group of mice receiving a lot of vaccine were divided into groups of five. Five mice (one group) were bled and the sera pooled for antibody determination. A group of five mice receiving each lot of vaccine and a control group of unvaccinated mice were then inoculated intranasally with increasing amounts (tenfold increases) of mouse lung passage influenza virus having an LDs0 titer of 10 6-s. The mice were then observed for death or survival over
TABLE III
Cross-Protectlon Tests with PR8-S and Variants Fd, Gf, and ttg of the Original Line
Experiment
No.
Challenge virus 100 LADso :~ Log EIDs0 48 hours after challenge.
dose of vaccine. Homologous a 14 day period. Those dying were examined for pulmonary consolidation and those surviving were sacrificed at 14 days and examined for lung lesions.
The results are shown in Fig. 1 . As can be seen, the three PR8-S virus vaccines provoked considerably more antibody than did the Fd/s variant vaccines of comparable strength. When the two vaccine groups of mice were challenged with the same amounts of respective homologous virus, in both groups as would be expected, the greatest number of deaths occurred in the group with the lowest antibody titers. However, more Fd/s-vaccinated mice died or showed lesions in all four challenge groups than did PR8-S vaccinated animals. Fd/s-vaccinated mice which survived challenge showed proportionally a greater boost in antibody titer than was found in the surviving PR8-S mice.
Cross-Protection Tests.--Cross-challenge protection tests were carried out as follows.
Mice of the same age and weight were employed. Three groups of mice were employed in each cross-challenge test. One served as controls, one was vaccinated intraperitoneally with the PR8-S virus vaccine and the other with a given variant vaccine. The group receiving the PR8-S vaccine were given two 0.5 ml. doses at 5 to 7 day intervals while those receiving the variant vaccines were given three 0.5 ml. doses in an attempt to produce corn- parable antibody levels. The viruses in the Fd/s, Gf/s, and Hg/s vaccines were concentrated tenfold by high speed centrifugation in order to produce reasonably comparable antibody titers to those elicited by the diluted PR8-S vaccines, Sufficient mice were vaccinated with each vaccine so that the prechallenge antibody titers would be determined on the pooled blood of five mice, another three were sacrificed at 48 hours after challenge to determine lung virus titers and at least ten mice used to determine deaths or survival rates.
The challenge tests were carried out from 10 to 14 days after the last vaccine inoculation. In the tests all challenge doses of virus were given by aerosol with one exception. The amount was 100 lethal ~ir-borne dosess0 (LADs0) given in a closed chamber. The LADs0 of each virus was previously determined by titration of tenfold dilutions nebulized in the closed chamber using ten mice for each dilution. Forty-eight hours after challenge three mice in each group were sacrificed and 10 per cent lung virus suspension prepared. The EIDs0 of these suspensions were determined. The mice were observed for 14 days after challenge for death or survival. Those alive at 14 days were sacrificed and pulmonary lesions noted.
The low challenge dose of virus was employed in order to avoid a break-through of homologous immunity and thus to increase the sensitivity of the cross-protection test. This along with the above observation of lung virus titer at 48 hours, death or survival and presence or absence of pulmonary lesions in surviving mice made it possible to detect differences in degrees of cross-protection among the variants and the original PR8-S virus.
In Table III are shown the results of cross-protection tests employing the fifth, sixth, and seventh variants of the first series and the PR8-S virus. In all three experiments all control mice challenged with the PR8-S virus or a variant showed comparable high titers in the lungs at 48 hours while mice challenged with homologous virus showed no virus at this time. The Fd-vaccinated mice was the only group which appeared to be completely resistant to challenge with the PR8-S virus since none died and no virus could be detected in the lungs at 48 hours. The mice vaccinated with Gf and Hg variants and challenged with PR8-S virus showed moderately high lung virus titers but two deaths and only one Ha-vaccinated mouse showed pulmonary lesions. On the other hand all PR8-S-vaccinated mice challenged with the variants showed high lung virus titers at 48 hours. Some in each group died and many surviving mice showed pulmonary lesions. The differences in the cross-immunity tests can be explained on the basis of the relative amounts of antibody provoked by the heterologous virus. PR8-S produced little or no antibody to the variants while the variants, with the exception of Gf, provoked considerable antibody to PR8-S. The degree of cross-protection between PR8-S and the Gf variant was greater than would be expected on the basis of antibody titers in the mice.
Cross-Protection Tests with PR8-S and the Variant Viruses of the Second
Series.--Cross-H.I. and in ovo neutralization and antibody absorption tests demonstrated a close antigenic similarity between Cb and its D/s variant.
In Table IV are shown the results of an experiment to compare the growth of Cb and D/s variants in the lungs of mice recovered from infections with PRS-S virus 6 weeks previously. Homologous challenge showed the mice to be solidly immune to growth in the lungs at 48 hours even at the highest challenge dose while Cb and D/s grew about equally well in the PR8-S-recovered mice. In the mice challenged with 100 LDs0 doses the titer of D/s virus was significantly higher than the Cb virus titers.
Cross-challenge tests with the Cb and its D/s variant and the PR8-S virus are shown EIDso.
in Table V . In these experiments all the unvaccinated control mice died and showed high lung virus titers at 48 hours. Solid, homologous immunity was also present. On the other hand, challenge of Cb-and D/s-vaccinated mice with PR8-S virus produced lung virus titers of 2.3 and 3.7 respectively. PR8-S-vaccinated mice challenged with Cb and D/s variants had virus titers of 6.5 and 8.0 respectively. These results also show the close similarity of these two variants as demonstrated previously by serological procedures. Both reacted in small amounts with the PRS-S antiserum and both produced antibody to the PR8-S virus almost or as great as the respective homologous titers. In Table VI are given the results of a cross-protection test with the second variant Fd/s of the second series and the PR8-S virus. Larger numbers of mice were employed so that virus titers in the lungs at six intervals after challenge could be determined. It can be seen that the two antisera possessed only a small amount of H.I. antibody for the respective heterologous virus. A small amount of demonstrable antibody was present for the PRS-S virus in Fd/s antiserum while there was little or no antibody to the Fd/s virus in the PR8-S antiserum. On challenge with the two viruses all the control mice died and showed high virus titers in the lungs. Homologous challenge demonstrated solid immunity with no virus being demonstrated at any of the post-inoculation time intervals. Heterologous infection was produced with both the PR8-S and Fd/s viruses. The infection was less severe in the Fd/s-vaccinated mice as indicated by the lower titer of virus in the lungs, no deaths, and only one lung lesion in the ten surviving mice. In the PR8-S vaccinated mice challenged with the Fd/s virus the virus titer persisted in the lungs at moderately high titer for 6 days. Two of ten mice died and eight of ten showed lesions in the lungs. Again it is demonstrated that the extent of cross-protection between these viruses appears to be greater than is reflected in their serological relationships.
The results of cross-protection tests with the third and fourth variants (Gf/s and Hg/s) the second series and the PRS-S virus are shown in Table   TABLE VII. These variants produced no antibody to the PR8-S virus and the PR8-S antiserum contained no antibody to the variants. The control mice in both experiments died and showed equally high virus titers in the lungs at 48 hours. Homologous challenge showed solid immunity as indicated by no virus being demonstrated in the lungs at 48 hours and no deaths or lesions in the mice. Heterologous challenge showed somewhat greater protection in the variant vaccinated mice infected with the PR8-S virus than occurred when the PR8-Svaccinated mice were challenged with the Gf/s and Hg/s variants. This is indicated by the higher virus titers in the lungs of the PR8-S-vaccinated mice and noted with the presence of pulmonary lesions in the surviving animals. Again the cross-protection tests reveal a much closer relationship than the serological tests would indicate.
DISCUSSION
Although the pathogenicity of the variants of the first and second series was similar to that of the original PR8-S virus therc was a progressive loss with each succeeding variant in the ability to provoke antibodics. This loss of antigenicity may be the result of the methods employcd in the development of the variant viruses. As they were all derived from their passage in the lungs of homologously immune mice, it might be expected that some of the more potent antigens in the virus complex would be selectively neutralized or suppressed by their specific antibody in the immune environment. Thus, the antigenic complex of each succeeding variant would be expected to contain less and less potent antigens. This appears to be the case for when the antigenic potency is compared in relation to the sequential deviation of the variants, a marked and progressive decline in the ability of the variants to provoke an antibody response in mice and ferrets can be seen.
The loss of antigenicity without a significant decrease in pathogenicity among thc variants of influenza PR8-S virus does not appear to correspond to P-Q variation as described by Van der Veen and Muldcr (3) and studied by Fiset and Depoux (4). The variants described here have been derived entirely by mouse passage. Q strains of influenza virus appear to arise mainly among egg-adapted viruses, after passage of P strains in eggs in the presence of homologous antiserum. Furthermore, Q strains can be converted to P strains by mouse passage, but all antigenic variants described in this and preceding reports appear to bc stable on passage in normal mice.
In all cross-protection tcsts with PR8-S parent virus and its variants, micc vaccinated with PR8-S virus were less resistant to challenge with variant viruses than mice vaccinated with variant viruses and challenged with PR8-S. This reflected the serological relationships shown between the variant viruses and PR8-S. All variants produced some antibody reacting with PR8-S but the variant viruses reacted slightly or not at all with the PR8-S antibody. Although Fd and Gf variants of the original line, and Fd/s and Gf/s variants of the Bar-S line produced significantly less PR8-S antibody than other variants of thesc two lines, mice vaccinated with these variants were not significantly less resistant to challenge with PR8-S than mice vaccinated with other variants. Although the serological procedures showed marked antigenic differences between the PR8-S virus and its variants these differences were not as well demonstrated in the cross-protection tests.
For instance, Fd and subsequent variants of the original line, and Fd/s variant and subsequent variants of the Bar-S line reacted little if at all with PR8-S antiserum, but mice vaccinated with PR8-S nevertheless showed some degree of resistance to challenge with these variants. Less than 50 per cent of these mice died. However, lung lesions and titcr of virus in lungs showcd that infection did occur.
In recent years little attention has been paid to correlation of serological differences with degree of cross-immunity in mice. In 1938 Francis and Magill (5) and Smith and Andrewes (6) concluded that serological differences among the type A strains of that time could be correlated in a general way with crossimmunity in mice. However, Francis and Magill (5) pointed out that single doses of vaccine often failed to immunize mice to homologous challenge, while multiple doses of vaccine increased the degree of cross-protection among strains. More recently Francis (7) reported that mice given two doses of Keffer '47 strain produced little antibody to Rhodes '47 virus, yet were resistant to log 5.0 LDs0 intranasal doses of Rhodes virus. Also, Herzberg, May, and Beck (8) recently reported that mice immunized with PR8-S influenza virus which produced no antibody to FM1 virus, did not all die when challenged intranasally with FM1 strain. In their experiments most of the surviving mice showed lung lesions indicating a high degree of infection. It appears from these studies that use of death or survival alone in cross-protection tests with influenza type A or A t strains is not sufficiently sensitive to correlate with even wide serological differences in the corresponding strains. The antigenic variants described in this report are more closely related to PR8-S than is FM1 virus. Therefore, it is hardly surprising that mice vaccinated with PR8-S and challenged with the most serologically different variants did not all die. By using virus titer of the lungs at 48 hours, as well as deaths and lung lesions, it is possible to demonstrate lack of complete reciprocal immunity among the variants and PR8-S virus. Thus, the results of cross-protection tests were in general agreement with serological findings, that is PR8-S vaccine protected least against challenge with those variants which reacted least with PR8-S antisera in the serological tests.
These studies demonstrate clearly the antigenic instability of influenza viruses when subjected to passage through a partially immune host. Whether the immune state of the human population has operated in a similar fashion to bring about the progressive antigenic changes in the group A influenza viruses since their first isolation in 1933 can only be surmised. These studies suggest that the alteration of antigenic components, in such a manner that older strains fail to provoke antibody against more recent ones, is essential to the survival of influenza virus in man. In recent years, it has been noted that influenza viruses have also shown a decrease in their capacity to provoke homologous as well as heterologous antibody but no decline in their ability to infect man in widespread epidemics. These observations have their counterpart in our studies of the production of variant influenza A (PR8) viruses following passage through immunized animals.
SI/MMARY
Two series of variants of influenza PR8-S virus have been described. While all retain the same degree of pathogenicity for mice and fertile eggs, there was a progressive loss in the ability of the variants to provoke antibody following vaccination or infection of mice and ferrets. The immunogenicity of the variants was, therefore, less than that of the original strain. Although little or no serological relationship could be demonstrated between some of the variants and the PR8-S virus a considerable degree of cross-immunity could be demonstrated in the cross-protection tests with these viruses if observations were based solely on death or survival of the mice. By employing the occurrence of lesions in the lung and the titer of virus in the lung 48 hours after challenge, the amount of cross-protection in mice could be related to the amount of serological cross-reaction. In general mice vaccinated with PR8-S virus were less resistant to infection with the variant viruses than mice vaccinated with variants and challenged with the PR8-S parent virus.
The role of the immune environment of the host in the production of the variant influenza viruses with their serological differences, decreasing antigenicity, and persisting pathogenicity as well as the epidemiological implications of these findings with respect to epidemic influenza in man are discussed.
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